Tropheryma whipplei

Associated infections

• Classic Whipple disease with malabsorption and weight loss
• Whipple arthropathy and chronic arthralgia
• Central nervous system Whipple disease
• Blood culture-negative infective endocarditis
• Uveitis and ocular involvement
• Acute gastroenteritis, particularly in children
• Pneumonia and bacteraemia
• Asymptomatic intestinal and oropharyngeal carriage

Transmission route

The available evidence supports faecal-oral and oral-oral transmission between humans. T. whipplei DNA has been detected in the influx to sewage treatment plants and at higher rates in the stool of sewage treatment workers than in comparison groups, indicating that human faecal material is the source of environmental detections rather than an independent environmental reservoir. Carriage in saliva and stool, intrafamilial clustering with shared genotypes between household members, and age-related prevalence patterns with early acquisition in childhood are all consistent with person-to-person spread within households and communities rather than with acquisition from soil or water.

The organism's reduced genome is itself informative about its ecology. Loss of biosynthetic capacity implies dependence on a host or a nutrient-rich environment, and there is no evidence of a free-living replicative niche. Detections in sewage represent transported human material, and detection in a matrix does not establish viability, since molecular assays detect DNA from non-viable organisms equally well.

T. whipplei is not a water-system organism and is not a valid target for reprocessing water surveillance. It cannot grow in purified water, has no described role in premise-plumbing biofilm, and would not be recovered by the heterotrophic plate count, membrane filtration or selective culture methods used for final rinse water testing. Even if organisms were introduced into a treated water system, there is no mechanism by which they would persist or amplify. Any consideration of this organism in a water context therefore begins not with the water but with the question of how a result naming it was generated at all.

Relevance in endoscopy and reprocessing

T. whipplei has no recognised association with endoscope reprocessing or with endoscopy-transmitted infection. There are no documented outbreaks, pseudo-outbreaks or transmission events attributed to contaminated endoscopes, reprocessing water, CSD water or dental water. The organism does not form biofilm in engineered water systems, does not survive independently in treated water, and has no described tolerance to high-level disinfectants or thermal processes beyond that of an ordinary vegetative bacterium. On the evidence available it presents no reprocessing-related infection risk, and this should be stated plainly rather than hedged.

Its relevance to endoscopy is diagnostic rather than infection-control. Duodenal biopsy obtained at upper gastrointestinal endoscopy is the principal specimen for confirming Whipple disease, and endoscopy units will therefore encounter the organism as a clinical entity in their patient population, not as an environmental one. Endoscopic appearances in the duodenum may be normal or may show pale, shaggy or oedematous mucosa, and multiple biopsies from the distal duodenum are recommended because involvement can be patchy. Where the diagnosis is suspected, the laboratory should be notified so that PAS staining, immunohistochemistry and molecular testing are performed rather than routine histology alone.

One indirect reprocessing consideration follows from this. Biopsy forceps and other accessories used to obtain such specimens are critical devices and are single-use or sterilised, so no high-level disinfection question arises. For the endoscope itself, the organism is a vegetative Gram-positive bacterium present in gastrointestinal tissue and content, and it would be inactivated by a validated high-level disinfection cycle in the same way as other vegetative flora. The one practical risk is analytical rather than biological: a unit that obtains Whipple disease specimens is a unit whose laboratory handles T. whipplei molecular material, which creates a route for cross-contamination of unrelated samples processed on the same platform. That possibility is what makes the surveillance discussion below the operative one for this organism.

Interpreting a detection

Any report of T. whipplei in connection with a water sample should be assessed first for methodological plausibility, because the organism cannot be recovered by any culture method used in routine reprocessing water surveillance. Heterotrophic plate counts, membrane filtration onto standard media and selective culture will never yield it. Only a molecular assay could generate such a result, and such assays are not part of routine water testing. The first question is therefore not what the water system is doing but what test was performed, who requested it, why, and against what specification. A result naming an organism that the applied method could not have detected is a data integrity problem before it is anything else.

Where a molecular result has genuinely been produced, three explanations should be excluded before any consideration is given to the water system. The first is cross-contamination within the laboratory, which is a well-recognised hazard of high-sensitivity amplification assays, particularly where positive controls or high-titre clinical material are handled in the same workspace. The second is carry-over from a clinical specimen processed on the same platform or in the same run, which is a realistic possibility in a laboratory that also performs Whipple disease testing on duodenal biopsy, stool or cerebrospinal fluid. The third is misassignment of the sample, through labelling error, transposition at accessioning, or a reporting error linking a clinical result to an environmental sample identifier. Reviewing the run controls, the position of the sample within the run, the identity of other samples processed alongside it, and the full chain of custody will usually resolve which applies.

Confirmation with an independent assay, ideally targeting a different genomic region, or by a reference laboratory, is warranted before the result is acted upon at all. It is also worth noting that a molecular detection establishes the presence of DNA, not of viable organisms, so even a technically valid result would not demonstrate a living organism in the water. No remediation of the water treatment plant, no suspension of reprocessing and no patient look-back should be initiated on the basis of an unconfirmed single molecular detection of this organism, and escalation is better directed at the laboratory and at the testing specification than at the water system. If a facility is receiving results for organisms outside the scope of its sampling programme, the appropriate corrective action is to review and formalise that programme so that the panel, the methods and the reporting align with the applicable standard and with what the results are actually capable of informing.

Antimicrobial resistance

There are no standardised antimicrobial susceptibility testing methods or breakpoints for T. whipplei, because the organism cannot be cultured by routine techniques. Susceptibility data derive from specialised cell culture and axenic systems available in a small number of laboratories, and from genome analysis, and the two approaches have not always agreed. This is an unusual situation clinically: treatment decisions rest on inference from genomic content and from accumulated case experience rather than on testing of the patient's own isolate.

Genomic work has shown that the organism lacks genes of the folate biosynthesis pathway that are targeted by one component of trimethoprim-sulfamethoxazole, implying that only the trimethoprim component contributes activity and that the combination is functionally a monotherapy. This has led to debate about its adequacy and to reports of treatment failure and relapse, including central nervous system relapse, on such regimens. Central nervous system relapse is the most feared outcome because it may occur years after apparently successful treatment and is difficult to reverse.

Contemporary practice commonly uses an induction phase with a parenteral agent such as ceftriaxone or meropenem, chosen in part for central nervous system penetration, followed by prolonged oral maintenance therapy. Doxycycline combined with hydroxychloroquine is used as an alternative to trimethoprim-sulfamethoxazole, the rationale being that alkalinisation of the phagolysosome by hydroxychloroquine restores doxycycline activity against an organism that resides in an acidic intracellular compartment. Prolonged treatment measured in months to years and long-term follow-up with repeat molecular testing are required because relapse is well described. Immune reconstitution inflammatory syndrome may complicate treatment, particularly in patients who received immunosuppression for presumed inflammatory arthritis before the diagnosis was made. None of these considerations has any bearing on water system management or on disinfectant selection in reprocessing, where the organism presents no described tolerance and no operational challenge.